Anoctamins are a class of calcium-activated chloride ion channels, which have been recently implicated in cancer pathogenesis. Researchers from Telethon Kids Institute and the University of Western Australia aimed to characterize the expression of the anoctamin family in diffuse midline glioma (DMG).
Undiagnosed bleeding disorders put people at risk due to bleeding without an optimal treatment strategy. Spanish researchers from the Hospital Universitario La Paz and Universidad Autónoma de Madrid have focused on the targeting of tissue factor pathway inhibitor (TFPI) as a potential approach for this medical need by using TFPI blocker antibodies.
Scientists at the University of Sydney have discovered a protein in the lung that blocks SARS-CoV-2 infection and forms a natural protective barrier in the human body. Leucine-rich repeat-containing protein 15 (LRRC15) is an inbuilt receptor that binds the SARS-CoV-2 virus without passing on the infection. The discovery opens a new area of immunology research around LRRC15 and suggests a pathway to develop new drugs to prevent viral infection from coronaviruses like COVID-19, but also to deal with fibrosis in the lungs.
Blueprint Medicines Corp. presents mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer and viral infections.
Cytokinetics Inc. has patented ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of cancer, obesity and cardiovascular, inflammatory, metabolic, muscle, neurological and renal disorders, among others.
Medshine Discovery Inc. has synthesized dual N-(2-aminophenyl)benzamide compounds acting as lysine-specific histone demethylase 1A (LSD1) and histone deacetylase 1 (HDAC1) inhibitors reported to be useful for the treatment of cancer.
Hookipa Pharma Inc. has achieved a US$10 million milestone payment under its collaboration agreement with Roche (F. Hoffmann-La Roche Ltd.) to develop HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers.
RSS
